Endo International PLC (ENDP) Debt Trading 3.5% Higher Analyst
An issue of Endo International PLC (NASDAQ:ENDP) debt rose 3.5% against its face value during trading on Wednesday after Royal Bank Of Canada lowered their price target on the stock from $26.00 to $21.00. The high-yield issue of debt has a 6% coupon and will mature on July 15, 2023. The bonds in the issue are now trading at $85.75 and were trading at $86.19 last week. Price changes in a company’s debt in credit markets often predict parallel changes in its share price.
A number of other analysts have also issued reports on ENDP. Piper Jaffray Cos. restated a “neutral” rating and set a $19.00 target price on shares of Endo International PLC in a research report on Tuesday, September 27th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Endo International PLC in a research report on Tuesday, September 27th. Leerink Swann restated a “hold” rating and set a $22.00 target price (down previously from $23.00) on shares of Endo International PLC in a research report on Tuesday, August 9th. Mizuho upgraded shares of Endo International PLC from a “neutral” rating to a “buy” rating and raised their target price for the stock from $16.00 to $29.00 in a research report on Friday, August 12th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $22.00 price target on shares of Endo International PLC in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Endo International PLC presently has an average rating of “Buy” and a consensus price target of $36.56.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC raised its position in Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock valued at $159,000 after buying an additional 4,597 shares during the period. Canada Pension Plan Investment Board raised its position in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares during the period. LS Investment Advisors LLC raised its position in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock valued at $213,000 after buying an additional 8,247 shares during the period. Icon Advisers Inc. Co. acquired a new position in Endo International PLC during the second quarter valued at approximately $218,000. Finally, IFP Advisors Inc raised its position in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares during the period. 96.61% of the stock is owned by institutional investors and hedge funds.
The company’s 50-day moving average is $19.69 and its 200-day moving average is $19.15. The firm’s market capitalization is $3.89 billion.
Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, November 8th. The company reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.20. The firm earned $894.30 million during the quarter, compared to analysts’ expectations of $862.47 million. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. The business’s quarterly revenue was up 18.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 EPS. On average, equities research analysts anticipate that Endo International PLC will post $4.55 earnings per share for the current fiscal year.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.